Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins

This article was originally published in The Pink Sheet Daily

Executive Summary

In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.


Related Content

Bioverativ Hits The Street Ready To Expand In Blood Disorders
Shire Exits Biosimilars, Streamlines Oncology Business


Related Companies

Related Deals